

Prednisolone-treatment induces hepatic insulin resistance in C57Bl/6J mice, measured by a newly developed whole body glucose test

Anke Laskewitz

Lab pediatrics

Center for liver, digestive and metabolic diseases

University medical center Groningen

The Netherlands



Ecopa meeting, 18-10-2008 Alicante



Introduction

Glucocorticoids


- Hormones produced by the adrenal gland under control of the hypothalamic–pituitary–adrenal axis
- Cortisol, corticosterone in rodents
- Endogenous role in salt and water metabolism, blood pressure, glucose metabolism, immune system
- Synthetic glucocorticoids used as immunosuppressive drugs in chronic inflammatory diseases



Severe side effects

Introduction

- Cardiovascular diseases
- Mood swings/
depression
- Weight gain
- Fat redistribution
- Hypertension
- Insulin resistance
- Growth retardation
- Impaired immune
respons
- Skin thinning
- Muscle wasting
- Osteoperosis
- Moon face




Cushing
syndrome

TiPharma Project

Project T1-106

Glucocorticoid-induced insulin resistance



Aim Identify the most important tissue(s) and mechanism(s) by which prednisolone induces metabolic side effects

Project strategy

Ouwens et al. LUMC

M. Linssen

- In vitro studies in adipocytes, muscle, and β cells
- Effects on glucose (uptake), lipolysis, adipokines
- Effects on insulin signal transduction (cell lines)
- Effects on Insulin signal transduction in primary human t

Kuipers et al. UMCG

A. Laskewitz

- In vivo studies in chow and high-fat fed mice
- Peripheral and hepatic insulin resistance
- Effects on metabolic fluxes
- Effects on islets (gene expression profiling)

Dokter et al.
Shering Plough Corp.

- In vitro & in vivo animal, clinical trial in healthy humans
- Prednisolone study in healthy human volunteers
- Study gene expression using micro-arrays
- Confrim data in arthritic mice

Diamant et al. VUmc

D. Van Raalte

- Clinical trial in healthy human volunteers (Pantheon)
- Various aspects of β -cell function and insulin resistance
- Metabolic fluxes and mitochondrial function
- incl fat and muscle biopsies

Bijlsma et al. UMCU

J. Hoes

M. van der Goes

- Clinical Trial in Rheumatoid Arthritis patients
- Various aspects of β -cell function and insulin resistance
- Effects on bone

Lems et al. VUmc

D. Den Uyl


- Clinical Trial in Rheumatoid Arthritis patients (COBRA Light)
- Various aspects of β -cell function and insulin resistance
- Effects on bone

Vitro

Pre-clinical
Vivo


Healthy
Humans

RA
Patients



Organs most likely to be involved

Muscle
Adipose




- ▶ insulin resistance
- ▶ glucose uptake
- ▶ muscle wasting

Brain




- ▶ insulin resistance
- ▶ glucose uptake
- ▶ mineralocorticoid action
- ▶ behavioural changes

Liver




- ▶ insulin resistance
- ▶ glucose production
- ▶ glucose uptake

Pancreas



- ▶ insulin resistance
- ▶ insulin secretion
- ▶ glucose sensing




- ▶ insulin resistance
- ▶ glucose uptake
- ▶ changes body fat content (chronic)
- ▶ change in adipokines

Aim


Determine the roles of liver and peripheral tissues in glucocorticoid-induced insulin resistance, employing mouse models

Measure development of insulin resistance by whole body glucose test

Experimental set-up




Method Whole Body Glucose Test



Method Whole Body Glucose Test

- Inject ip trace amount [6,6-²H]-glucose
- Measure blood glucose levels every 10 min
- Take a blood spot on filter paper every 10 min
- Extract glucose from bloodspots and derivatise to glucose-pentaacetate
- Analyse by GC-MS to obtain fractional contribution of [6,6-²H]-glucose



$$C_t = (C_0^{el} * e^{-k_{el}t}) - (C_0^{ab} * e^{-k_{ab}t})$$

Method Whole Body Glucose Test

Parameter		Formula
[6,6- ² H]-glucose concentration	blood	$C_t = C_0 * e^{-kt}$
		$C_t^{el} = C_0^{el} * e^{-k_{el}t}$
		$C_t^{ab} = C_0^{ab} * e^{-k_{ab}t} * C_0^{el}$
[6,6- ² H]-glucose in blood over time		$C_t = (C_0^{el} * e^{-k_{el}t}) - (C_0^{ab} * e^{-k_{ab}t})$
Lag time		$t_{lag} = (\ln(C_0^{ab}) - \ln(C_0^{el})) / (k_{ab} - k_{el})$
[6,6- ² H]-glucose concentration at t_{lag}	blood	$C_{lag} = C_0^{el} * e^{-k_{el}t_{lag}}$
		$C_{lag} = C_0^{ab} * e^{-k_{ab}t_{lag}}$
Bioavailability		$F = 1 - ((C_0^{ab} * k_{el}) / (k_{ab} * C_0^{el}))$
Volume of distribution		$V = (F * D) / C_{lag}$
Amount of glucose in the sampled		$A = V * [glc]$


Results

Basal values


Plasma	Control	Prednisolone	High fat
Glucose fasted (mmol/l)	7.37 ± 1.45	8.79 ± 2.00	7.58 ± 0.89
Insulin (mU/l)	1.44 ± 0.15	2.9 ± 1.34 *	7.40 ± 6.80 #
HOMA	0.96 ± 0.47	2.32 ± 2.59	3.59 ± 3.44 #
Corticosterone (ug/l)	889 ± 196	167 ± 116 *	820 ± 98
Cholesterol (mM)	2.96 ± 0.32	3.38 ± 0.61	5.85 ± 0.41 #
Triglycerides (mM)	0.74 ± 0.19	1.03 ± 0.28 *	1.29 ± 0.18 #
NEFA (μM)	472 ± 76	449 ± 99	580 ± 72
Liver			
Cholesterol (nmol/mg liver)	10.80 ± 0.88	9.59 ± 1.93	11.77 ± 1.99
Free Cholesterol (nmol/mg liver)	7.41 ± 0.88	6.43 ± 1.17	7.19 ± 1.53
Triglycerides (nmol/mg liver)	19.37 ± 8.48	17.18 ± 6.70	43.72 ± 16.92#
Glvcoaden (umol/gr)	91 ± 72	97 ± 113	111 ± 76

Results

Average glucose levels during whole body glucose test




Average insulin levels after whole body glucose test




Results

Endogenous glucose production by whole body glucose test



Metabolic clearance rate whole body glucose test



Conclusion

- Prednisolone treatment induces hepatic insulin resistance, shown by increased endogenous glucose production
- A high fat diet induces peripheral insulin resistance, shown by decreased metabolic clearance
- The whole body glucose test is a good method to measure and discriminate between hepatic and peripheral insulin resistance
→ Using stable isotopes more information can be obtained from one animal

Conclusion

Whole body glucose test versus 'gold standard' hyperinsulinemic euglycemic clamp

Advantages

- 1- no surgery
- 2- fast
- 3- less invasive
- 4- repeatable, so you can measure development over time
- 5- cheaper
- 6- basal situation, not a tolerance test
- 7- own control

Dissadvantage

- 1- less information about insulin levels
- 2- glucose and insulin levels are not adjustable
- 3- not hyperinsulinemic

Acknowledgements

UMCG

Theo van Dijk
Aldo Grefhorst
Juul Baller
Theo Boer
Dirk-Jan Reijngoud
Folkert Kuipers

Schering-Pough corp.

Wim Dokter
Marie-José van Lierop

